US 2025/0049863 A1 · USE OF POSTBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ANXIETY DISORDERS

Use of postbiotics in the treatment and/or prevention of anxiety disorders

AssigneeBiopolis, S.L.

InventorsMaria Empar CHENOLL CUADROS, Patricia MARTORELL GUEROLA, Marta TORTAJADA SERRA, Daniel RAMÓN VIDAL, Antonia ROJAS MARTÍNEZ, Ferran BALAGUER VIDAL, Silvia LLOPIS PLA, Roberto MARTÍNEZ ÁVILA, Vanesa ROBLES RODRÍGUEZ, Marta FERNÁNDEZ RIESCO

Life of this patent

Estimating the term…

Abstract

The present invention relates to a postbiotic composition comprising non-viable Bifidobacterium longum and Lactobacillus rhamnosus strains and its related use in the treatment and/or prevention of anxiety disorders.

Claims12

Dependent claims

Postbiotic composition comprising non-viable Bifidobacterium longum strain CECT 7347 and non-viable Lactobacillus rhamnosus strain CECT 8361.

Dependencies are inferred from the claim text.

Facts

Application

18/719,647Filed 16 Dec 2022

Priority

EP 21383147.216 Dec 2021

Published

13 Feb 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 35/745
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs: bifidobacteria
A61K 35/747
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs: lactobacilli, e.g. L. acidophilus or L. brevis
A61P 25/22
Drugs for disorders of the nervous system: anxiolytics
A61P 25/24
Drugs for disorders of the nervous system: antidepressants